Screening of novel HSP-inducing compounds to conserve cardiomyocyte function in experimental atrial fibrillation

André Heeres, Hu Xu (First author), Denise MS van Marion (First author), Femke Hoogstra-Berends, Deli Zhang, Jean-Paul Seerden, Lizette Loen, Herman Steen, Robert H Henning, Bianca J J M Brundel

Research output: Contribution to journal › Article › Academic › peer-review

10 Downloads (Pure)

Abstract

Background: The heat shock protein (HSP) inducer, geranylgeranylacetone (GGA), was previously found to protect against atrial fibrillation (AF) remodeling in experimental model systems. Clinical application of GGA in AF is limited, due to low systemic concentrations owing to the hydrophobic character of GGA.

Objectives: To identify novel HSP-inducing compounds, with improved physicochemical properties, that prevent contractile dysfunction in experimental model systems for AF.
Original languageEnglish
Pages (from-to) 345—364
JournalDrug design, development and therapy
Volume13
Publication statusPublished - 18 Jan 2019

Keywords

  • atrial fibrillation
  • heat shock protein
  • drosophila
  • proteostasis
  • geranylger­anylacetone

Cite this

Heeres, A., Xu , H., van Marion, D. MS., Hoogstra-Berends, F., Zhang, D., Seerden, J-P., ... Brundel, B. J. J. M. (2019). Screening of novel HSP-inducing compounds to conserve cardiomyocyte function in experimental atrial fibrillation. Drug design, development and therapy, 13, 345—364 .
Heeres, André ; Xu , Hu ; van Marion, Denise MS ; Hoogstra-Berends, Femke ; Zhang, Deli ; Seerden, Jean-Paul ; Loen, Lizette ; Steen, Herman ; Henning, Robert H ; Brundel, Bianca J J M. / Screening of novel HSP-inducing compounds to conserve cardiomyocyte function in experimental atrial fibrillation. In: Drug design, development and therapy. 2019 ; Vol. 13. pp. 345—364 .
@article{ef625647f17546f9936c7670b3195a54,
title = "Screening of novel HSP-inducing compounds to conserve cardiomyocyte function in experimental atrial fibrillation",
abstract = "Background: The heat shock protein (HSP) inducer, geranylgeranylacetone (GGA), was previously found to protect against atrial fibrillation (AF) remodeling in experimental model systems. Clinical application of GGA in AF is limited, due to low systemic concentrations owing to the hydrophobic character of GGA.Objectives: To identify novel HSP-inducing compounds, with improved physicochemical properties, that prevent contractile dysfunction in experimental model systems for AF.",
keywords = "atrial fibrillation, heat shock protein, drosophila, proteostasis, geranylger­anylacetone, hartaandoeningen",
author = "Andr{\'e} Heeres and Hu Xu and {van Marion}, {Denise MS} and Femke Hoogstra-Berends and Deli Zhang and Jean-Paul Seerden and Lizette Loen and Herman Steen and Henning, {Robert H} and Brundel, {Bianca J J M}",
year = "2019",
month = "1",
day = "18",
language = "English",
volume = "13",
pages = "345—364",
journal = "Drug design, development and therapy",
issn = "1177-8881",
publisher = "Dove Press Limited",

}

Heeres, A, Xu , H, van Marion, DMS, Hoogstra-Berends, F, Zhang, D, Seerden, J-P, Loen, L, Steen, H, Henning, RH & Brundel, BJJM 2019, 'Screening of novel HSP-inducing compounds to conserve cardiomyocyte function in experimental atrial fibrillation' Drug design, development and therapy, vol. 13, pp. 345—364 .

Screening of novel HSP-inducing compounds to conserve cardiomyocyte function in experimental atrial fibrillation. / Heeres, André; Xu , Hu (First author); van Marion, Denise MS (First author); Hoogstra-Berends, Femke; Zhang, Deli; Seerden, Jean-Paul; Loen, Lizette; Steen, Herman; Henning, Robert H; Brundel, Bianca J J M.

In: Drug design, development and therapy, Vol. 13, 18.01.2019, p. 345—364 .

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Screening of novel HSP-inducing compounds to conserve cardiomyocyte function in experimental atrial fibrillation

AU - Heeres, André

AU - Xu , Hu

AU - van Marion, Denise MS

AU - Hoogstra-Berends, Femke

AU - Zhang, Deli

AU - Seerden, Jean-Paul

AU - Loen, Lizette

AU - Steen, Herman

AU - Henning, Robert H

AU - Brundel, Bianca J J M

PY - 2019/1/18

Y1 - 2019/1/18

N2 - Background: The heat shock protein (HSP) inducer, geranylgeranylacetone (GGA), was previously found to protect against atrial fibrillation (AF) remodeling in experimental model systems. Clinical application of GGA in AF is limited, due to low systemic concentrations owing to the hydrophobic character of GGA.Objectives: To identify novel HSP-inducing compounds, with improved physicochemical properties, that prevent contractile dysfunction in experimental model systems for AF.

AB - Background: The heat shock protein (HSP) inducer, geranylgeranylacetone (GGA), was previously found to protect against atrial fibrillation (AF) remodeling in experimental model systems. Clinical application of GGA in AF is limited, due to low systemic concentrations owing to the hydrophobic character of GGA.Objectives: To identify novel HSP-inducing compounds, with improved physicochemical properties, that prevent contractile dysfunction in experimental model systems for AF.

KW - atrial fibrillation

KW - heat shock protein

KW - drosophila

KW - proteostasis

KW - geranylger­anylacetone

KW - hartaandoeningen

M3 - Article

VL - 13

SP - 345—364

JO - Drug design, development and therapy

JF - Drug design, development and therapy

SN - 1177-8881

ER -

Heeres A, Xu H, van Marion DMS, Hoogstra-Berends F, Zhang D, Seerden J-P et al. Screening of novel HSP-inducing compounds to conserve cardiomyocyte function in experimental atrial fibrillation. Drug design, development and therapy. 2019 Jan 18;13: 345—364 .

Access to Document